We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 524

ACCC conditionally clears NestlePfizer deal
  • Herbert Smith Freehills LLP
  • Australia
  • November 30 2012

On 22 November 2012, the Australian Competition and Consumer Commission (ACCC) announced it would not oppose the proposal by Nestlé SA to acquire the global infant nutrition business of Pfizer Inc (the transaction), subject to court enforceable undertakings

Generic pharmaceuticals and competition law: the ACCC vs Pfizer proceedings
  • Corrs Chambers Westgarth
  • Australia
  • March 10 2014

The ACCC has commenced proceedings in the Federal Court against Pfizer Australia Pty Ltd (Pfizer) alleging that commercial offers made by Pfizer to

European Commission ups the cost of paying for delay
  • King & Wood Mallesons
  • Australia, European Union, USA
  • August 13 2012

On 25 July 2012, the EC alleged that Danish pharmaceutical company Lundbeck violated EU antitrust rules by colluding to prevent other pharma companies from marketing generic versions of its best-seller antidepressant, citalopram

Australian court fines Baxter almost A$5 million for abuse of market power
  • Rajah & Tann Asia LLP
  • Australia
  • October 18 2010

On 26 August 2010, The Full Federal Court of Australia imposed a penalty of A$4,9 million on Baxter Healthcare Pty Limited (‘Baxter’)for violations of section 46 (taking advantage of market power) and section 47 (exclusive dealing) of the Trade Practices Act 1974 (‘TPA’

Competition regulators continue their campaign against pharmaceutical companies
  • King & Wood Mallesons
  • Australia, USA
  • June 1 2011

Last month, the US Federal Trade Commission (FTC) released its findings on reverse payment settlements between pharmaceutical companies in the 2010 US fiscal year

Managing your risks under global anti-corruption regimes
  • Piper Alderman
  • Australia, United Kingdom, USA
  • September 13 2012

Pharmaceutical and medical device companies operate in a stringent regulatory environment

Collective bargaining
  • Gilbert + Tobin
  • Australia
  • August 22 2012

The ACCC proposes to allow St Vincent’s Private Hospital Sydney to join other members of the St Vincent’s Health Australia Group (these other members being related bodies corporate) in the collective and joint activity of the group, effectively enabling them to operate as a single economic entity

European developments: to regulate or not to regulate - that is the question?
  • Clayton Utz
  • Australia
  • September 30 2009

Australian manufacturers and suppliers who export products to the EU should keep in mind that reforms across a number of fronts could have an impact on their business

Penalties for unconscious breaches of the Trade Practices Act
  • PwC Australia
  • Australia
  • September 14 2010

On 27 August 2010, the Federal Court ordered Baxter Healthcare Pty Ltd (Baxter) to pay penalties of $4.9 million in respect of contraventions of sections 46(1)(c) and 47(1) of the Trade Practices Act (1974) (the TPA

Recent mergers approved in the pharmaceutical industry
  • Herbert Smith Freehills LLP
  • Australia
  • November 12 2009

The ACCC has announced that it will not oppose two proposed acquisitions in the pharmaceutical sector: the proposed acquisition of Wyeth Corp by Pfizer Inc, and the proposed acquisition of Merck & Co Inc by Schering-Plough Corporation